Warfarin in non-valvular atrial fibrillation

South African Medical Journal

Volumn 103, Issue 12, 2013, Pages 901-904

  Dalby, Anthony J ^a   Wessels, Pieter ^b   Opie, Lionel H ^c  

^a MILPARK HOSPITAL   (South Africa)

^b Ampath   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anitcoagulants; Non valvular atrial fibrillation; Warfarin

Indexed keywords

ANTIBIOTIC AGENT; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG ACTIVITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; RISK FACTOR; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; HEMORRHAGE; HUMANS; MEDICATION THERAPY MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; STROKE; WARFARIN;

EID: 84889599188     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.7172     Document Type: Article

References (31)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999; 131(7): 492-501. [http://dx. doi. org/10. 7326/0003-4819-131-7-199910050-00003].
2. Shulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133(6 Suppl): 257S-298S. [http://dx. doi. org/10. 1378/chest. 08-0674].
3. Rose AJ, Ozonoff A, Grant RW, et al. The epidemiology of sub-therapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2: 591-597. [http://dx. doi. org/10. 1161/CIRCOUTCOMES. 109. 862763].
4. Petersen P, Grind M, Adler J; SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: A dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003; 41(9): 1445-1451.
5. Samsa GP, Matcher DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation. Arch Intern Med 2000; 160(7): 967-973. [http://dx. doi. org/10. 1001/archinte. 160. 7. 967].
6. Camm AJ, Kirchof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31(19): 2369-2429. [http://dx. doi. org/10. 1093/eurheartj/ehq278].
7. Camm AJ, Lip GYH, de Caterina R, et al. 2012 focussed update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33(21): 2719-2747. [http://dx. doi. org/10. 1093/eurheartj/ehs253].
8. Gross CP, Vogel EW, Dohnd AJ, et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey. Clin Ther 2003; 25(6): 1750-1764. [http://dx. doi. org/10. 1016/S0149-2918(03)80167-4].
9. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish Atrial Fibrillation Cohort Study. Circulation 2012; 125(19): 2298-2307. [http://dx. doi. org/10. 1161/CIRCULATIONAHA. 111. 055079].
10. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the Vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(6 Suppl): 160S-198S. [http://dx. doi. org/10. 1378/chest. 08-0670].
11. van Spall HGC, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for variations in the quality of anticoagulation control between centers and countries: An analysis of patients receiving warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Circulation 2012; 126(19): 2309-2316. [http://dx. doi. org/10. 1161/CIRCULATIONAHA. 112. 101808].
12. Heidbuchel H, Verhamme P, Ailings M, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15(5): 625-651. [http://dx. doi. org/10. 1093/europace/eut083].
13. Tait CR, Mumford AD, Laffan M. British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160(1): 35-46. [http://dx. doi. org/10. 1111/bjh. 12107].
14. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: Systematic review and meta-analysis of individual patient data. Lancet 2012; 379(9813): 322-334. [http://dx. doi. org/10. 1016/S0140-6736(11)61294-4].
15. Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleveland Clinic J Med 2009; 76(Suppl 4): S37-S44. [http://dx. doi. org/10. 3949/ccjm. 76. s4. 07].
16. Birnie DH, Healey JS, Wells GA, et al. Pacemaker of defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368: 2084-2093. [http://dx. doi. org/10. 1056/NEJMoa1302946].
17. Schulman S, Elbazi R, Zondag M, et al. Clinical factors influencing normalization of prothrombin time after stopping warfarin: A retrospective cohort study. Thromb J 2008; 16: 15. [http://dx. doi. org/10. 1186/1477-9560-6-15].
18. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011; 155(2): 137-149. [http://dx. doi. org/10. 1111/j. 1365-2141. 2011. 08826. x].
19. Baruch L. Laboratory monitoring of anticoagulant medications: Focus on the novel oral anticoagulants. Postgrad Med 2013; 125(2): 135-145. [http://dx. doi. org/10. 3810/pgm. 2013. 03. 2647].
20. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368: 2113-2124 [http://dx. doi. org/10. 1056/NEJMra1206531].
21. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e326S-e350S. [http://dx. doi. org/10. 1378/chest. 11-2298].
22. Siegal S, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving Vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126(13): 1630-1639. [http://dx. doi. org/10. 1161/CIRCULATIONAHA. 112. 105221].
23. David JS, Piriou V, Albaadejo P. Letter by David et al. regarding article, 'Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) randomized trial'. Circulation 2013; 127: e504. [http://dx. doi. org/10. 1161/CIRCULATIONAHA. 112. 133041].
24. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165(10): 1095-1106. [http://dx. doi. org/10. 1001/archinte. 165. 10. 1095].
25. Halbritter K, Beyer-Westendorf J, Nowotny J, et al. Hospitalization for vitamin-K-antagonist-related bleeding: Treatment patterns and outcome. J Thromb Haemost 2013; 11(4): 651-659. [http://dx. doi. org/10. 1111/jth. 12148].
26. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J 2012; 33(22): 2821-2830. [http://dx. doi. org/10. 1093/eurheartj/ehs274].
27. Kleinow ME, Garwood CL, Clemente CL, Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 2011; 17(7): 523-530.
28. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(11): 2599-2604. [http://dx. doi. org/10. 2215/CJN. 02400311].
29. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012; 8: 569-578. [http://dx. doi. org/10. 1038/nrneph. 2012. 160].
30. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: A nationwide study. BMJ Open 2013; 3: e002758. [http://dx. doi. org/10. 1136/bmjopen-2013-002758].
31. Patel MR, Hellkamp AS, Lokhnygina Y. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013; 61(6): 651-658. [http://dx. doi. org/10. 1016/j. jacc. 2012. 09. 057].